Multicenter randomized controlled clinical trial comparing ebastine and mebeverine as
treatment of irritable bowel syndrome
Trial rationale
1. To perform a randomized superiority trial comparing the clinical efficacy of ebastine
and mebeverine
2. To evaluate the impact of treatment with ebastine compared to mebeverine on quality of
life and quality-adjusted life years
Primary objective To provide further evidence of the superiority of histamine 1 receptor
antagonism as novel treatment for patients with non-constipated IBS, as compared to
mebeverine, one of the spasmolytics currently used as first line treatment of IBS.
Secondary objective(s) To provide evidence that the histamine 1 receptor antagonist ebastine
is more effective in reducing abdominal pain compared to the commonly used antispasmodic
mebeverine